Abstract 3725
Background
Photoimmunotherapy (PIT) is a platform technology that utilizes a photoactivatable dye conjugated to a cancer-targeting antibody. RM-1929 is composed of anti-EGFR antibody cetuximab and IRDye® 700DX. Binding of RM-1929 to EGFR followed by tumor illumination with non-thermal red light elicits rapid necrosis of EGFR-expressing cancer cells. RM-1929 PIT treatment was evaluated in a Phase 1/2a trial in patients with rHNSCC who failed multiple standard of care therapies, and demonstrated a favorable safety profile and resulted in positive response rates (Cognetti et al. ASCO 2019). Here we report preliminary data from exploratory biomarker studies from this study.
Methods
Phase 1 included 9 patients and Phase 2a cohort 30 patients. Pre-treatment biopsies and blood were collected within 12 months and 2 weeks prior to treatment, respectively. Post-treatment biopsies and blood samples were collected after cycle 1 and multiple time points during treatment cycles, respectively. EGFR and PD-L1 IHC expression and plasma cytokines levels were measured. PBMCs were phenotyped using innate and adaptive immune-marker panels.
Results
In 25 patients with pre-treatment biopsies, no trend was observed between EGFR expression and best target tumour response. In 12 patients for which pre- and post-treatment biopsies were available, EGFR expression was maintained in residual tumour after RM-1929 PIT treatment. Additionally, treatment was associated with induction of PD-L1 expression in tumour and immune cells in 10 out of 12 cases. In 13 samples tested, elevated baseline plasma cytokine levels were observed in 4 of 7 responders (3 of 4 CR and 1 of 3 PR) and 1 of 6 non-responders (1 of 5 SD and 0 of 1 PD). Immunophenotyping of whole blood showed systemic induction of innate and adaptive immunity (e.g. NK cells, cytokines, lymphocytes, monocytes, CD4 and CD8 T-cells) after treatment in 15 of 18 patients.
Conclusions
Biomarker analysis in this limited data set provided evidence of potential activation of innate and adaptive immunity following RM-1929 PIT treatment. Further evaluation of these biomarkers will be conducted in a Phase 3 trial (NCT03769506).
Clinical trial identification
NCT02422979.
Editorial acknowledgement
Legal entity responsible for the study
Rakuten Medical, Inc.
Funding
Rakuten Medical, Inc.
Disclosure
J.D. Bui: Advisory / Consultancy: Rakuten Medical, Inc.; Advisory / Consultancy, Research grant / Funding (self): Ignyta, Inc.; Shareholder / Stockholder / Stock options: Paramita Therapeutics. N. Suslov: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. D. Yadav: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. J. Fong: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. E. Sun: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. M. Haedo: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. M. Garcia-Guzman: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc.
Resources from the same session
2507 - KEYLYNK-010: Phase 3 Study of Pembrolizumab (pembro) Plus Olaparib (OLA) vs Enzalutamide (ENZA) or Abiraterone (ABI) in ENZA- or ABI-Pretreated Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Had Progression on Chemotherapy (CTx)
Presenter: Evan Yu
Session: Poster Display session 3
Resources:
Abstract
2944 - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastasic hormone-sensitive prostate cancer.
Presenter: Jose Arranz Arija
Session: Poster Display session 3
Resources:
Abstract
3535 - A phase 1 study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ben Tran
Session: Poster Display session 3
Resources:
Abstract
4951 - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer (EudraCT: 2018-002350-78, NCT03903835)
Presenter: Johan Lindberg
Session: Poster Display session 3
Resources:
Abstract
2892 - A phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
2427 - The Extended/Phase II Study of Safety And Tolerability Of Proxalutamide (GT0918) In Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone (Abi) Or Enzalutamide (Enza)
Presenter: Nicholas Vogelzang
Session: Poster Display session 3
Resources:
Abstract
3224 - Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer
Presenter: Marit Vermunt
Session: Poster Display session 3
Resources:
Abstract
3312 - A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy.
Presenter: Piet Dirix
Session: Poster Display session 3
Resources:
Abstract
2829 - Health-Related Quality of Life (HRQoL) and Updated Follow-Up From KEYNOTE-057: Phase 2 Study of Pembrolizumab (pembro) for Patients (pts) With High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG)
Presenter: Ronald de Wit
Session: Poster Display session 3
Resources:
Abstract
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract